Syros Pharmaceuticals, Inc. Stock price
Is Syros Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Syros Pharmaceuticals, Inc. Stock Analysis
Analyst Opinions
6 Analysts have issued a Syros Pharmaceuticals, Inc. forecast:
Analyst Opinions
6 Analysts have issued a Syros Pharmaceuticals, Inc. forecast:
Don't miss a Thing! We will send you all news about Syros Pharmaceuticals, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425 and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
| Head office | United States |
| CEO | Gerald Quirk |
| Employees | 68 |
| Founded | 2011 |
| Website | syros.com |


